🌎 Headlines and Analyst Ratings for 12/27/2023

Ratings changes for Coherus BioSciences, PayPal, Tesla, Iovance Biotherapeutics, Central Garden & Pet, Expedia Group, Camden National and more...Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial. Unsubscribe.

VIEW MY PORTFOLIO

December 27th, 2023

Forget NVDA. Buy this A.I. stock instead (ad) Dozens of 100% - 1,000% opportunities over the last decade have led to this one under-the-radar A.I. stock... More here. Today's Top Stories Synopsys offers to acquire Ansys, sparks stock surge Was 2023 a tipping point for movies? 'Barbie' success and Marvel struggles may signal a shift "Chilling War Games Show US Forces Crushed" – FOX NEWS (Behind the Markets) Buffett keeps buying Occidental Petroleum, should you?  The New York Times sues OpenAI, Microsoft over the use of its stories to train chatbots The most upgraded stocks from 2023: buy, sell or hold? The year in clean energy: Wind, solar and batteries grow despite economic challenges BREAKING: Tiny biotech successfully treats blindness (Behind the Markets) The truth behind NIO's 60.0% upside Edmunds: The best plug-in hybrids for driving without filling up on gas Liquidia: Court victory the awakening of an industry giant? US online retailer Zulily says it will go into liquidation, surprising customers Quick Links MarketBeat All Access My MarketBeat Account Settings Mobile App Analyst Ratings Company Profiles Dividend Declarations Earnings Announcements Headlines Insider Trades Insider Buying Stocks Insider Selling Stocks Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's (ad) A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>> Click here to learn more Your Watchlist You have not added any stocks to your watchlist. Click here to add stocks to your watchlist. Analysts' Upgrades Fusion Pharmaceuticals (NASDAQ:FUSN) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $15.00 price target on the stock, up previously from $12.00. This represents a 69.5% upside from the current price of $8.85. Outlook Therapeutics (NASDAQ:OTLK) was upgraded by analysts at Capital One Financial Co. from an "equal weight" rating to an "overweight" rating. They now have a $5.00 price target on the stock. This represents a 979.0% upside from the current price of $0.46. View today's most recent analysts' upgrades at MarketBeat.com The World's First "$20 Trillion Drug"? (ad) The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>> Pentagon Consultant—Here's how Biden Wins Landslide Re-election (ad) —but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take, detailed here… Analysts' New Coverage PMV Pharmaceuticals (NASDAQ:PMVP) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $7.00 price target on the stock. This represents a 122.9% upside from the current price of $3.14. View today's most recent analysts' new coverage at MarketBeat.com Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. START YOUR 30-DAY FREE TRIAL Calendars from MarketBeat U.S. Analyst Ratings Corporate Buybacks Cryptocurrencies Dividend Declarations Earnings Announcements Economic Reports Gap Up/Down Stocks Insider Trades Initial Public Offerings (IPOs) Most Active Stocks Percentage Gainers/Decliners Sector Performance Short Interest Unusual Options Volume Unusual Trading Volume Upgrade Your Subscription Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. UPGRADE NOW Manage Your Watchlist View and add up to five holdings to your watchlist. VIEW MY PORTFOLIO Join Our Facebook Group Join MarketBeat's free stock discussion and trading idea group on Facebook. JOIN NOW

Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Unlock the Power of Tomorrow with the #1 Alternative Energy Stock! (Click to Subscribe + Get 2 Free Bonuses)